Mounjaro®▼ (tirzepatide) 2.5 mg KwikPen® – shelf-life extension
Eli Lilly and Company (Lilly) in agreement with the Medicines and Healthcare product Regulatory Agency (MHRA) has announced an extension to the shelf-life of Mounjaro®▼ (tirzepatide) 2.5mg KwikPen® from 9 months to 14 months for the following batches :
| Product | Batch No. | Displayed/Printed Expiry Date |
New Expiry Date | Dear Patient Letter link |
| Mounjaro® 2.5mg KwikPen® solution for injection in prefilled pen | D712074 | 05-2024 | 10-2024 | Mounjaro®-2.5mg-KwikPen®_Patient-Letter-1_D712074.pdf |
| Mounjaro® 2.5mg KwikPen® solution for injection in prefilled pen | D720751 D720957 |
09-2024 | 02-2025 | Mounjaro®-2.5mg-KwikPen®_Patient-Letter-2_D720751_D720957.pdf |
The affected Mounjaro® packs within these batches, will not be re-labelled, but will be inserted into a sealed clear plastic bag with a letter advising the patients to follow the New Expiry Date. Please note this is applicable to the above mentioned batches only, any other batches should continue to be used as normal. Additional information can be found in the ‘Dear HCP Letter‘ and the ‘Pharmacy FAQ Document‘ produced by Eli Lily to support pharmacy teams.
Eli Lily say ‘There are no product quality, safety or efficacy concerns related to the affected Mounjaro® 2.5mg KwikPen® batches. If needed, please reassure patients and caregivers that their medication can be taken and will continue to work safely and as intended until the end of the new expiry date.’
This medicine is subject to additional monitoring. This includes any possible side effects not listed in the package leaflet. This will allow quick identification of new safety information. You can help by reporting any side effects you may get, see www.mhra.gov.uk/yellowcard.
For more information or to report adverse event information among patients taking Mounjaro®, please contact Lilly Medical Information department at: 01256 315000 or via email: ukmedinfo@lilly.com.
